| 1478 |
National Cancer Institute |
Html |
en |
Skin Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of skin cancer. |
| treatment | 0.409923 |
| metastatic basal cell | 0.400394 |
| subsequent basal cell | 0.391984 |
| Skin Cancer Prevention | 0.365074 |
| Arch Dermatol | 0.471327 |
| photodynamic therapy | 0.399886 |
| sun-exposed skin | 0.375699 |
| skin cancers | 0.433811 |
| primary skin cancers | 0.370681 |
| uncomplicated basal cell | 0.398522 |
| basal-cell carcinoma | 0.373761 |
| PUBMED Abstract | 0.376972 |
| Mohs micrographic surgery | 0.406259 |
| Invest Dermatol | 0.363857 |
| prior skin cancer | 0.363746 |
| multiple basal cell | 0.397256 |
| nonmelanoma skin cancers | 0.400983 |
| recurrence rates | 0.396208 |
| Dermatol Surg Oncol | 0.421496 |
| periocular basal cell | 0.39808 |
| BCC | 0.370104 |
| Abstract | 0.389392 |
| main skin cancer | 0.382703 |
| basal cell nevus | 0.404293 |
|
| squamous cell carcinomas | 0.385705 |
| eyelid addresses carcinomas | 0.365517 |
| non-eyelid skin cancers | 0.367643 |
| surgical excision | 0.369879 |
| Br J Dermatol | 0.407426 |
| cosmetic results | 0.379562 |
| superficial basal cell | 0.487048 |
| skin cancer awareness | 0.383438 |
| basal cell carcinomas | 0.527823 |
| nodular skin BCCs | 0.369486 |
| nodular basal cell | 0.432753 |
| nonmelanoma skin cancers. | 0.373768 |
| nevoid Basal cell | 0.396437 |
| primary superficial basal | 0.391239 |
| radiation therapy | 0.475907 |
| nonmelanoma skin cancer | 0.483068 |
| basal cell carcinoma | 0.980145 |
| regional lymph nodes | 0.369237 |
| radiation therapy treatment | 0.376744 |
| longstanding skin ulcers | 0.361677 |
| et al. | 0.442813 |
| Acad Dermatol | 0.422124 |
| squamous cell carcinoma | 0.41423 |
|
CLICK HERE |
| 1541 |
National Cancer Institute |
Html |
en |
Testicular Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of testicular cancer. |
| tumor marker levels | 0.613741 |
| cancer treatment | 0.320393 |
| testicle | 0.4399 |
| testicular cancer spreads | 0.297436 |
| contains cancer cells | 0.273957 |
| body | 0.340237 |
| PDQ cancer information | 0.333395 |
| testicular cancer | 0.725943 |
| testicular germ cell | 0.272075 |
| clinical trial search | 0.331245 |
| long-term follow-up | 0.27959 |
| clinical trials | 0.622305 |
| undescended testicle | 0.275057 |
| cancer information summary | 0.310365 |
| clinical trial | 0.428741 |
| spermatic cord | 0.329024 |
| tumor markers | 0.368096 |
| inguinal orchiectomy | 0.361937 |
| patients | 0.336056 |
| malignant tumor cells | 0.300585 |
| NCI PDQ cancer | 0.275949 |
| lymph nodes | 0.529321 |
| radiation therapy | 0.376906 |
| Serum tumor marker | 0.305709 |
| general cancer information | 0.270473 |
|
| treatment | 0.469864 |
| general information | 0.294195 |
| NCI-supported cancer | 0.288405 |
| cancer cells | 0.405185 |
| Recurrent testicular cancer | 0.320003 |
| Cancer Information Service | 0.271409 |
| treatment clinical trials | 0.292646 |
| National Cancer Institute | 0.350045 |
| lymph vessels | 0.288149 |
| new treatment | 0.293694 |
| distant lymph nodes | 0.317031 |
| combination chemotherapy | 0.304741 |
| Testicular Cancer Treatment | 0.305239 |
| metastatic tumor | 0.2721 |
| blood | 0.282323 |
| tumor marker test | 0.304459 |
| retroperitoneal lymph nodes | 0.28218 |
| cancer clinical trials | 0.344359 |
| stage | 0.329917 |
| testicular tumor | 0.289398 |
| comprehensive cancer information | 0.269733 |
| cancer | 0.908321 |
| information | 0.339805 |
| following tumor markers | 0.277178 |
|
CLICK HERE |
| 1688 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cancer treatment | 0.54874 |
| PDQ Cannabis | 0.53541 |
| PDQ cancer information | 0.561631 |
| Cancer Complementary | 0.483651 |
| cancer therapy | 0.493942 |
| clinical trials | 0.738523 |
| cannabinoid receptors | 0.573547 |
| advanced cancer patients | 0.489779 |
| U.S. Food | 0.49892 |
| cancer information summary | 0.529639 |
| National Institutes | 0.485607 |
| alternative cancer therapies | 0.482187 |
| clinical trial | 0.556349 |
| cancer therapies | 0.496308 |
| patients | 0.580973 |
| cancer patients | 0.559766 |
| Cannabis users | 0.54158 |
| Investigational New Drug | 0.490753 |
| NCI PDQ cancer | 0.493719 |
| cancer information database | 0.48226 |
| effects | 0.498728 |
| cannabinoids | 0.769857 |
| main active cannabinoid | 0.509915 |
| treatment | 0.563891 |
|
| breast cancer cells | 0.497802 |
| Cannabis plant extract | 0.540785 |
| United States | 0.581783 |
| Cannabis plant | 0.559258 |
| Complementary Therapies Editorial | 0.487662 |
| Drug Administration | 0.596753 |
| Cancer Information Specialist | 0.479354 |
| cancer cells | 0.516435 |
| Cancer Information Service | 0.529301 |
| Cannabis extract | 0.551963 |
| National Cancer Institute | 0.60295 |
| studies | 0.507275 |
| alternative medicine | 0.50524 |
| pain relief | 0.516491 |
| advanced cancer | 0.497262 |
| approved research settings | 0.478938 |
| cannabis | 0.903862 |
| chemotherapy-related nausea | 0.514076 |
| cancer cell death | 0.500487 |
| medicinal Cannabis | 0.540165 |
| cancer clinical trials | 0.488981 |
| alternative therapies | 0.483937 |
| cancer information summaries | 0.482387 |
| cancer | 0.807964 |
|
CLICK HERE |
| 1741 |
National Cancer Institute |
Html |
en |
Menopausal Hormone Therapy and Cancer |
A fact sheet about the results of research on menopausal hormone therapy (MHT). Includes information about the effect of MHT on the body and benefits and risks of using menopausal hormones. |
| M. Menopausal hormone | 0.399446 |
| estrogen | 0.661955 |
| progestin | 0.473666 |
| menopausal symptoms | 0.433158 |
| lung cancer | 0.436349 |
| postmenopausal estrogen | 0.401234 |
| Anderson GL | 0.391175 |
| Breast Cancer Research | 0.404812 |
| MHT | 0.573747 |
| placebo | 0.469804 |
| whi estrogen-plus-progestin study | 0.43139 |
| colorectal cancer | 0.510049 |
| breast cancer survivors | 0.442442 |
| vertebral fractures | 0.396082 |
| hormone therapy group | 0.403745 |
| hormone therapy medication | 0.406528 |
| hot flashes | 0.474358 |
| invasive breast cancer | 0.436727 |
| hormone replacement therapy | 0.391432 |
| Health Initiative | 0.489409 |
| randomized clinical trials | 0.471592 |
| menopausal hormone therapy | 0.725067 |
| WHI trials | 0.489874 |
| health effects | 0.386028 |
| women | 0.908896 |
|
| MHT change | 0.392923 |
| breast cancer detection | 0.43656 |
| Non-FDA-approved hormone products | 0.402601 |
| One-third lower risk | 0.39906 |
| breast cancer recurrence | 0.408176 |
| breast cancers | 0.398762 |
| estrogen-alone MHT | 0.393357 |
| 10,000 women | 0.558208 |
| National Cancer Institute | 0.442573 |
| natural hormones estrogen | 0.458568 |
| hormone therapy | 0.86696 |
| combined hormone therapy | 0.473354 |
| postmenopausal women | 0.502051 |
| absolute terms | 0.40498 |
| breast cancer | 0.990788 |
| WHI Estrogen-Alone Study | 0.441842 |
| Chlebowski RT | 0.451885 |
| randomized controlled trial | 0.389145 |
| healthy postmenopausal women | 0.397371 |
| et al | 0.576891 |
| New England Journal | 0.390547 |
| breast cancer incidence | 0.436953 |
| Women’s Health | 0.429633 |
| risk | 0.448458 |
|
CLICK HERE |
| 1894 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas. |
| radiocirugÃa estereotáctica | 0.521736 |
| cuáles ganglios | 0.544229 |
| estadio iv | 0.535294 |
| pequeño corte | 0.516426 |
| sustancia llamada fcev | 0.511226 |
| faja ajustadora | 0.518847 |
| pequeña cantidad | 0.570347 |
| Silbido respiratorio | 0.522024 |
| cáncer.ampliar broncoscopia | 0.521373 |
| gen alk | 0.51503 |
| cáncer.ampliar mediastinoscopÃa | 0.517089 |
| células normales.ampliar exploración | 0.600106 |
| cuerpo.ampliar radiografÃa | 0.522592 |
| estadios ia | 0.514018 |
| rayos x | 0.552576 |
| estadio ib | 0.557189 |
| estadio ia | 0.556394 |
| enlace drugs approved | 0.531609 |
| ondas sonoras | 0.51647 |
| Non-Small Cell Lung | 0.531866 |
| células t | 0.528626 |
| vÃas respiratorias | 0.808836 |
|
| carcinoma epidermoide | 0.525518 |
| numerosos ensayos | 0.516625 |
| pecho.ampliar biopsia | 0.526618 |
| estadios iia | 0.515213 |
| estadio iiia | 0.625519 |
| determinadas células | 0.530359 |
| antecedentes familiares | 0.518918 |
| alta potencia | 0.516655 |
| estadio iia | 0.557019 |
| tirosina cinasa | 0.692486 |
| Cell Lung Cancer | 0.531364 |
| siguientes sitios | 0.51534 |
| siguientes situaciones | 0.666362 |
| ecografÃa ayuda | 0.515534 |
| principal factor | 0.576142 |
| áreas.ampliar biopsia | 0.52208 |
| siguientes formas | 0.529859 |
| bronquiolos.ampliar anatomÃa | 0.52368 |
| siguientes sumarios | 0.532291 |
| siguientes pruebas | 0.527678 |
| vasos sanguÃneos | 0.979174 |
|
CLICK HERE |
| 1951 |
National Cancer Institute |
Html |
es |
Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos. |
| siguientes procedimientos | 0.408317 |
| displasia multilinaje | 0.404818 |
| células madre | 0.698581 |
| leucemia aguda | 0.40611 |
| sÃndromes mielodisplásicos | 0.99284 |
| hueso compacto | 0.416921 |
| neoplasias mieloides | 0.402645 |
| plaquetas maduras | 0.410918 |
| célula madre mieloide | 0.437557 |
| National Cancer Institute | 0.402744 |
| siguientes riesgos | 0.401921 |
| vitamina b12 | 0.403995 |
|
| Instituto Nacional | 0.404912 |
| PDQ Tratamiento | 0.439829 |
| célula madre linfoide | 0.43173 |
| vidrio piezas | 0.403146 |
| neoplasias mielodisplásicas | 0.404775 |
| displasia unilinaje | 0.404747 |
| Physician Data Query | 0.410747 |
| cáncer.ampliar trasplante | 0.403337 |
| leucemia mieloide aguda | 0.59748 |
| célula madre | 0.50311 |
| células sanguÃneas maduras | 0.465531 |
| siguientes pruebas | 0.40454 |
|
CLICK HERE |
| 2025 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer colorrectal (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre las pruebas que se usan para detectar el cáncer colorrectal. |
| PDQ Exámenes | 0.849253 |
| Physician Data Query | 0.949845 |
| sigmoidoscopia causa | 0.801378 |
| tubo recolector | 0.784476 |
| Estados Unidos | 0.979222 |
| riesgos.Los exámenes | 0.85829 |
| cuerpo).ampliar anatomÃa | 0.797555 |
| prevención revisa | 0.744583 |
| radiografÃas llamada | 0.774966 |
|
| PDQ Prevención | 0.956837 |
| pequeño aumento | 0.790999 |
| siguientes exámenes | 0.980519 |
| información ayuda | 0.751125 |
| National Cancer Institute | 0.760892 |
| siguientes riesgos | 0.742979 |
| siguientes sumarios | 0.885224 |
| Instituto Nacional | 0.814155 |
|
CLICK HERE |
| 3651 |
National Cancer Institute |
Html |
en |
TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy |
A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes. |
| adjuvant chemotherapy | 0.787463 |
| higher recurrence scores | 0.454387 |
| 21-gene recurrence score | 0.676351 |
| mid-range score | 0.364833 |
| postsurgical chemotherapy | 0.404675 |
| Jo Anne Zujewski | 0.399515 |
| Cancer Therapy Evaluation | 0.426635 |
| National Clinical Trials | 0.404942 |
| adult cancer research | 0.415943 |
| early-stage breast cancer | 0.44803 |
| Montefiore Medical Center | 0.406438 |
| test’s ability | 0.364803 |
| lowest 21-gene recurrence | 0.476043 |
| patients | 0.383684 |
| 5-year recurrence rates | 0.497417 |
| Trial Assigning Individualized | 0.434763 |
| hormone receptor-positive breast | 0.606376 |
| gene panel test | 0.401972 |
| high risk | 0.363068 |
| primary breast cancers | 0.421261 |
| women | 0.592588 |
| low risk | 0.421557 |
| United States | 0.429126 |
| ECOG-ACRIN Research Group | 0.402947 |
|
| low-risk subset | 0.454616 |
| breast cancer recurrence | 0.516723 |
| percent | 0.443551 |
| Initial findings | 0.364086 |
| hormone receptor-positive disease | 0.474523 |
| 10,000 women | 0.389687 |
| molecular test | 0.368711 |
| 21-gene panel test | 0.405027 |
| various treatment options | 0.412166 |
| hormone therapy | 0.89376 |
| aromatase inhibitor therapy | 0.427967 |
| primary cancer events | 0.412638 |
| NCIC-Clinical Trials Group | 0.404753 |
| postoperative treatment | 0.371444 |
| estrogen receptor | 0.368053 |
| early-stage hormone | 0.432936 |
| breast cancer | 0.917923 |
| 21-gene recurrence test | 0.48221 |
| Recurrence events | 0.412295 |
| breast cancer mortality | 0.453698 |
| -positive breast cancer | 0.464645 |
| New England Journal | 0.424409 |
| HER2-negative breast cancer | 0.446932 |
| journal article | 0.367547 |
|
CLICK HERE |
| 16693 |
National Cancer Institute |
Html |
en |
In an Era of Precision Medicine, Testing New Approaches to Breast Cancer Screening |
An NCI research article about individualized approaches that could help identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk. |
| clinical DNA testing | 0.255296 |
| certain genetic alterations | 0.26295 |
| Family Comprehensive Cancer | 0.304528 |
| early molecular changes | 0.250583 |
| Breast Cancer Surveillance | 0.393407 |
| Dr. Szabo | 0.324259 |
| Breast Care Center | 0.362601 |
| ovarian cancer patients | 0.316413 |
| clinical trial | 0.331236 |
| breast cancer prevention | 0.392842 |
| breast density | 0.431317 |
| annual mammography | 0.280302 |
| risk-based group | 0.308284 |
| breast MRI | 0.280239 |
| Dr. Tice | 0.272786 |
| molecular changes | 0.271002 |
| seminal clinical trials | 0.251623 |
| Consortium Risk Calculator | 0.280953 |
| risk-based approach | 0.302169 |
| high risk | 0.287254 |
| precision medicine | 0.358439 |
| genetic markers | 0.26055 |
| women | 0.30866 |
| risk-based screening arm | 0.644595 |
| annual mammograms | 0.27926 |
|
| hereditary breast | 0.275314 |
| cancer screening | 0.642713 |
| cancer prevention | 0.415329 |
| HBOC—for genetic alterations | 0.253144 |
| risk-based screening strategies | 0.470957 |
| advanced-stage breast cancers | 0.351274 |
| family medical history | 0.264412 |
| General Internal Medicine | 0.258705 |
| Cancer MoonshotSM Blue | 0.314025 |
| risk-based screening | 0.987559 |
| false-positive test results | 0.2742 |
| lowest risk scores | 0.302649 |
| strongest risk factor | 0.279896 |
| breast cancer risk | 0.568335 |
| screening interval | 0.333337 |
| breast cancer | 0.836019 |
| genetic alterations | 0.266377 |
| annual screening group | 0.404487 |
| risk factor | 0.298033 |
| precision cancer prevention | 0.325999 |
| risk prediction model | 0.28587 |
| WISDOM trial | 0.343878 |
| highest risk scores | 0.301801 |
| ovarian cancer syndrome | 0.315021 |
|
CLICK HERE |
| 16829 |
National Cancer Institute |
Html |
en |
Cancer Driver Discovery Program |
null |
| large number | 0.638311 |
| tumor biology | 0.66038 |
| rare driver events | 0.719635 |
| comprehensive genomic characterization | 0.740363 |
| genomic analyses | 0.633135 |
| patient responses | 0.721865 |
| tumor tissues | 0.638276 |
| additional driver mutations | 0.771411 |
| lung cancer | 0.952268 |
| statistical models | 0.628862 |
| statistical power | 0.629897 |
| cancer genomics | 0.65394 |
| recurrent mutations | 0.655852 |
| patients | 0.702611 |
| Genomic Data Commons | 0.762952 |
| clinical trial N0147 | 0.722969 |
| Lung Cancer project | 0.792668 |
| molecular causes | 0.642033 |
| oncogenic process | 0.640394 |
| public health impact | 0.739202 |
| epidermal growth factor | 0.708102 |
| tumor types | 0.658904 |
| Cancer Driver Discovery | 0.8155 |
| DNA sequencing | 0.651327 |
| Cancer Research UK | 0.776689 |
|
| RNA sequence | 0.636519 |
| associated follow-up information | 0.721592 |
| ovarian cancers | 0.639935 |
| better treatment options | 0.776737 |
| clinical outcomes | 0.638824 |
| Foundation Lung Cancer | 0.793933 |
| intratumoral heterogeneity | 0.742723 |
| deeper characterization | 0.652385 |
| TRACERx collaborators | 0.637079 |
| NCI-funded clinical trial | 0.73112 |
| Genome Characterization Pipeline | 0.748856 |
| driver mutations | 0.919706 |
| St. James | 0.824605 |
| Tracking Cancer Evolution | 0.775958 |
| CCG | 0.851349 |
| colon cancer | 0.744767 |
| lung adenocarcinoma | 0.669686 |
| TRACERx study | 0.634122 |
| total RNA sequencing | 0.961331 |
| Cancer Genome Atlas | 0.832019 |
| chemotherapy regimen | 0.639583 |
| particular lung cancer | 0.807795 |
| Central Cancer Treatment | 0.762707 |
| genome sequencing | 0.685209 |
|
CLICK HERE |